R R Streiff
Overview
Explore the profile of R R Streiff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
234
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Skidmore F, Drago V, Foster P, Schmalfuss I, Heilman K, Streiff R
J Neurol Neurosurg Psychiatry
. 2007 Oct;
79(4):467-70.
PMID: 17911185
Background: Hereditary aceruloplasminaemia is a disorder of iron metabolism that is characterised by iron accumulation in the brain and other visceral organs. In previously reported cases, individuals with the disorder...
2.
Streiff R, BENDER J
Invest New Drugs
. 2001 Apr;
19(1):29-39.
PMID: 11291831
Unlabelled: This was a dose escalation Phase 1 trial designed to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of DENSPM. Methods: Adult patients with refractory solid tumors...
3.
Bergeron R, Merriman R, Olson S, Wiegand J, Bender J, Streiff R, et al.
Cancer Res
. 2000 Sep;
60(16):4433-9.
PMID: 10969789
The tissue distribution, metabolic profile, and pharmacokinetic parameters of i.v.-administered N1,N11-diethylnorspermine (DENSPM) are evaluated in Cebus apella primates, and the results are compared with data gathered from canine and human...
4.
Bergeron R, Weimar W, Luchetta G, Streiff R, Wiegand J, Perrin J, et al.
Drug Metab Dispos
. 1995 Oct;
23(10):1117-25.
PMID: 8654201
The pharmacokinetics and metabolism of N1,N11-diethylnorspermine (DENSPM) is described. When administered to dogs as an intravenous bolus, DENSPM was shown to have a plasma half-life of 72.8 +/- 11.8 min,...
5.
Bergeron R, Streiff R, King W, Daniels Jr R, Wiegand J
Blood
. 1993 Oct;
82(8):2552-7.
PMID: 8400302
A comparative study of the iron-clearing properties of subcutaneously administered desferrioxamine and parabactin is presented. The evaluation was performed in both a non-iron-overloaded bile-duct cannulated rat and an iron-loaded Cebus...
6.
Streiff R
Med Clin North Am
. 1993 Jul;
77(4):911-8.
PMID: 8321078
Hospitalized patients may present with nutritional deficiencies or develop them during the hospitalization. The physician should remain alert to the presence of these readily correctable conditions.
7.
Bergeron R, Streiff R, Creary E, Daniels Jr R, King W, Luchetta G, et al.
Blood
. 1993 Apr;
81(8):2166-73.
PMID: 8471775
A comparative study of the iron-clearing properties of subcutaneously administered desferrioxamine B (DFO) with those of orally administered desferrithiocin sodium salt (1), desmethyl desferrithiocin (2), desazadesmethyl desferrithiocin sodium salt (3),...
8.
Bergeron R, Streiff R, Wiegand J, Luchetta G, Creary E, Peter H
Blood
. 1992 Apr;
79(7):1882-90.
PMID: 1558978
A comparative study of the iron-clearing properties of subcutaneously (SC) administered deferoxamine (DFO) with those of orally administered 1,2-dimethyl-3-hydroxypyrid-4-one (CP20) and 1,2-diethyl-3-hydroxypyrid-4-one (CP94) is presented. The studies were performed in...
9.
Bergeron R, Streiff R, Wiegand J, Vinson J, Luchetta G, Evans K, et al.
Ann N Y Acad Sci
. 1990 Jan;
612:378-93.
PMID: 2127168
A comparative study of the non-iron-overloaded, bile duct-cannulated rat and of the Cebus monkey as iron-clearance models is presented. The ability of desferrioxamine, desferrithiocin, and a pyridoxal isonicotinoyl hydrazone (PIH)...
10.
Bergeron R, Streiff R, Elliott G
J Nutr
. 1985 Mar;
115(3):369-74.
PMID: 3973748
The ability of iron to stimulate the growth of L1210 cells both in DBA-2 mice and in cell culture is evaluated. Although in vitro stimulation is absent, in vivo studies...